Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

Lignende værker

• Shared scheme for assessing drugs for multiple sclerosis: Cost effective provision of effective treatments for multiple sclerosis
  af: Napier, Jacqueline C, et al.
  Udgivet: (2003)
• Shared scheme for assessing drugs for multiple sclerosis: Dealing with uncertainties about cost effectiveness of treatments is difficult problem
  af: Chadwick, David, et al.
  Udgivet: (2003)
• Shared scheme for assessing drugs for multiple sclerosis: Why are eyes tightly shut to considering causes other than autoimmunity?
  af: Chaudhuri, Abhijit, et al.
  Udgivet: (2003)
• Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
  af: Palace, Jacqueline, et al.
  Udgivet: (2019)
• UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
  af: Palace, Jacqueline, et al.
  Udgivet: (2014)